| |
PROLOGUE
Insurance Coverage Of Biopharmaceuticals
| The first 100 words of the full text of this article appear below. |
It is by now readily apparent to all concerned that new, breakthrough biopharmaceuticals pose a difficult challenge to existing arrangements for financing care because of their high costs, the small patient populations they often serve, and problems in measuring their incremental therapeutic value. How the U.S. health system deals with this challenge will reflect its unique and intricate mix of public and private institutions and processes. In a shift from an earlier era of scientific exploration financed primarily by government, the discoveries that paved the way for todays biopharmaceuticals have been underwritten by private investors as well as public sources. . . . [Full Text of this Article]

What's this?
|